Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe
Capri23auto / Pixabay

Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

According to a publication from BNN Bloomberg, regulatory authorities in the European Commission recently granted conditional marketing authorization (CMA) to Zynteglo. Zynteglo is a gene therapy designed to treat beta…

Continue Reading Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe